Literature DB >> 15219968

The "effects" of Rev-1 vaccination of sheep and goats on human brucellosis in Greece.

A Minas1, M Minas, A Stournara, S Tselepidis.   

Abstract

Vaccination of young animals (3-6-month-old sheep and goats) with Rev-1 vaccine for 15 years in Greece, importantly decreased the abortions in sheep and goats as well as the incidence of brucellosis in humans. After the stop of vaccination in 1994, all over Greece, the prevalence of brucellosis in animals and the incidence in humans quickly increased. It was a positive rank correlation (0.90) among these variables. Once an emergency mass-vaccination programme of young and adult animals with Rev-1 vaccine was started in 1998, the human incidence again decreased. The association of the vaccination coverage of animals and incidence of brucellosis in humans was not linear; the decrease in human brucellosis incidence was observed when the vaccination coverage of animals was >30%.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15219968     DOI: 10.1016/j.prevetmed.2004.03.007

Source DB:  PubMed          Journal:  Prev Vet Med        ISSN: 0167-5877            Impact factor:   2.670


  13 in total

1.  Prevalence and risk factors for brucellosis in goats in areas of Mexico with and without brucellosis control campaign.

Authors:  David Oseguera Montiel; Klaas Frankena; Henk Udo; Nícola Maria Keilbach Baer; Akke van der Zijpp
Journal:  Trop Anim Health Prod       Date:  2013-02-19       Impact factor: 1.559

2.  Progress in Brucella vaccine development.

Authors:  Xinghong Yang; Jerod A Skyberg; Ling Cao; Beata Clapp; Theresa Thornburg; David W Pascual
Journal:  Front Biol (Beijing)       Date:  2013-02-01

3.  Deletion of the GI-2 integrase and the wbkA flanking transposase improves the stability of Brucella melitensis Rev 1 vaccine.

Authors:  Marcos Mancilla; María-Jesús Grilló; María-Jesús de Miguel; Ignacio López-Goñi; Beatriz San-Román; Ana Zabalza-Baranguá; Ignacio Moriyón
Journal:  Vet Res       Date:  2013-10-31       Impact factor: 3.683

4.  Narrative overview of animal and human brucellosis in Morocco: intensification of livestock production as a driver for emergence?

Authors:  Marie J Ducrotoy; Khaoula Ammary; Hicham Ait Lbacha; Zaid Zouagui; Virginie Mick; Laura Prevost; Ward Bryssinckx; Susan C Welburn; Abdelali Benkirane
Journal:  Infect Dis Poverty       Date:  2015-12-22       Impact factor: 4.520

5.  Efficient Transduction and Expansion of Ovine Macrophages for Gene Therapy Implementations.

Authors:  Garyfalia Karponi; Spyridon Kritas; Evanthia Petridou; Eleni Papanikolaou
Journal:  Vet Sci       Date:  2018-06-18

6.  Development of a CRISPR/Cas9 system against ruminant animal brucellosis.

Authors:  Garyfalia Karponi; Spyridon K Kritas; Gina Papadopoulou; Elissavet-Kalliopi Akrioti; Eleni Papanikolaou; Evanthia Petridou
Journal:  BMC Vet Res       Date:  2019-11-27       Impact factor: 2.741

Review 7.  A history of the development of Brucella vaccines.

Authors:  Eric Daniel Avila-Calderón; Ahidé Lopez-Merino; Nammalwar Sriranganathan; Stephen M Boyle; Araceli Contreras-Rodríguez
Journal:  Biomed Res Int       Date:  2013-06-03       Impact factor: 3.411

8.  Incidence of human brucellosis in a rural area in Western Greece after the implementation of a vaccination programme against animal brucellosis.

Authors:  Eleni Jelastopulu; Christos Bikas; Chrysanthos Petropoulos; Michalis Leotsinidis
Journal:  BMC Public Health       Date:  2008-07-17       Impact factor: 3.295

9.  Vaccination control programs for multiple livestock host species: an age-stratified, seasonal transmission model for brucellosis control in endemic settings.

Authors:  Wendy Beauvais; Imadidden Musallam; Javier Guitian
Journal:  Parasit Vectors       Date:  2016-01-30       Impact factor: 3.876

Review 10.  Development and trial of vaccines against Brucella.

Authors:  Jonathan Lalsiamthara; John Hwa Lee
Journal:  J Vet Sci       Date:  2017-08-31       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.